Home > News > featured news > WELL Health Enters into Automatic Share Purchase Plan

Future of Healthcare

WELL Health Enters into Automatic Share Purchase Plan

WELL Health Technologies Corp. | June 16, 2022

WELL Health

WELL Health Technologies Corp.ca company focused on positively impacting health outcomes by leveraging technology to empower practitioners and their patients globally, announced today that it has entered into an automatic share purchase plancwith a broker in order to facilitate repurchases of the Company's common shares under its previously announced normal course issuer bid. 

WELL previously announced that it had received approval from the Toronto Stock Exchange to, during the 12-month period commencing June 1, 2022 and terminating May 31, 2023, purchase up to 5,555,386 Common Shares, representing approximately 2.5% of the 222,215,443 Common Shares issued and outstanding as of May 30, 2022, by way of a NCIB on the TSX or through alternative trading systems or by such other means as may be permitted under applicable law.

During the effective period of WELL's ASPP, WELL's broker may purchase Common Shares at times when WELL would not be active in the market due to insider trading rules and its own internal trading blackout periods. Purchases will be made by WELL's broker based upon parameters set by WELL when it is not in possession of any undisclosed material information about itself and its securities, and in accordance with the terms of the ASPP. Outside of the effective period of the ASPP, Common Shares may continue to be purchased in accordance with WELL's discretion, subject to applicable law. The ASPP has been entered into in accordance with the requirements of applicable Canadian securities laws.

About WELL Health Technologies Corp.
WELL is a practitioner focused digital healthcare company whose overarching objective is to positively impact health outcomes to empower and support healthcare practitioners and their patients. WELL has built an innovative practitioner enablement platform that includes comprehensive end to end practice management tools inclusive of virtual care and digital patient engagement capabilities as well as Electronic Medical Records (EMR), Revenue Cycle Management (RCM) and data protection services. WELL uses this platform to power healthcare practitioners both inside and outside of WELL's own omni-channel patient services offerings. As such, WELL owns and operates Canada's largest network of outpatient medical clinics serving primary and specialized healthcare services and is the provider of a leading multinational, multi-disciplinary telehealth offering. WELL is publicly traded on the Toronto Stock Exchange under the symbol "WELL" and is part of the TSX Composite Index. The Company also trades on the OTCQX Markets under the symbol "WHTCF". 

Spotlight

Digital Therapeutics

Welcome to a transformative world of healthcare empowered by Digital Therapeutics. In this rapidly evolving field, digital technologies are revolutionizing how we prevent, treat, and manage medical conditions, putting healthcare directly in the hands of individuals.

More featured news

Spotlight

Digital Therapeutics

Welcome to a transformative world of healthcare empowered by Digital Therapeutics. In this rapidly evolving field, digital technologies are revolutionizing how we prevent, treat, and manage medical conditions, putting healthcare directly in the hands of individuals.

Related News

Health Technology

TeleVox Secures Odeza's Patient Engagement Unit from Ensemble Health

TeleVox | September 11, 2023

TeleVox and Ensemble will provide Ensemble's clients with an all-encompassing healthcare solution, from patient acquisition to post-discharge care. This announcement is yet another significant milestone in TeleVox's continuous rapid growth and expansion journey. This acquisition underscores TeleVox's commitment to strengthening its presence in the healthcare sector as it integrates Odeza's patient engagement business. TeleVox, a distinguished provider of state-of-the-art omnichannel digital patient engagement technology, has completed a significant acquisition by owning the Odeza patient engagement business from Ensemble Health Partners (Ensemble). Ensemble, recognized as a preeminent force in revenue cycle management, specializes in delivering its services to various healthcare institutions, including hospitals, health systems, and physician practices. TeleVox and Ensemble are committed to extending the reach and accessibility of TeleVox's cutting-edge technology to Ensemble's existing customer base. This strategic endeavor aims to deliver healthcare providers an all-encompassing solution that seamlessly caters to a broad spectrum of healthcare requirements, commencing with the initial patient acquisition phase and extending throughout the entirety of the patient journey. This comprehensive approach encompasses not only the discharge process but extends into subsequent phases of aftercare and beyond, equipping healthcare institutions with the essential tools and resources to optimize patient engagement, streamline operational workflows, and elevate the overall quality of care delivery. Additionally, this move positions TeleVox to enhance its capabilities further in providing innovative solutions, enabling healthcare providers to engage with patients in a more comprehensive and technologically advanced manner, ultimately advancing the healthcare industry. Vik Krishnan, President of TeleVox, expressed his welcome to Odeza joining the TeleVox family and highlighted that the acquisition of Odeza's patient engagement business aligns with TeleVox's longstanding commitment to tailored communication solutions for enhancing the patient experience, solidifying TeleVox's position as an industry leader. He also emphasized that making their patient engagement solutions accessible to Ensemble's extensive customer base will enable more healthcare providers to deliver exceptional patient care. Judson Ivy, Founder, President and CEO of Ensemble Health Partners, remarked, "This partnership strengthens each of our positions in the healthcare industry and delivers unmatched value to our customers." Meanwhile, the company unveiled Iris, an AI-powered omnichannel conversational virtual assistant tailored for healthcare providers, in April. The introduction of an automated reputation management solution in the month that followed this significant development gave hospitals, health systems, and physician practices the ability to manage and improve their online presence effectively.

Read More

Health Technology

Biosense Webster Launches the OPTRELL™ Mapping Catheter with TRUEref™ Technology for Mapping of Complex Cardiac Arrhythmias

PRNewswire | July 25, 2023

Biosense Webster, Inc., a global leader in cardiac arrhythmia treatment and part of Johnson & Johnson MedTech,i announced the U.S. launch of the OPTRELL™ Mapping Catheter with TRUEref™ Technology powered by the CARTO® 3 System. The OPTRELL™ Mapping Catheter is a high-density diagnostic catheter, with small electrodes arranged in a fixed array formation to provide high-definition electrophysiological mapping of complex cardiac arrhythmia cases like persistent atrial fibrillation (AFib), redo AFib ablation, atrial tachycardia, and ventricular tachycardia. Cardiac arrhythmias are a growing epidemic. AFib is the most common type of cardiac arrhythmia and impacts nearly 40 million people worldwide, with up to 6 million of these individuals living in the U.S.1,2 AFib is a progressive disease, and if left untreated can get worse over time or lead to other serious complications like heart disease or stroke.3,4 Catheter ablation is a safe and effective procedure to restore the heart's incorrect electrical signals, which causes an abnormal heart rhythm.5 This new catheter includes 48 electrodes symmetrically distributed across and along six splines and combines with the CARTO® 3 System to deliver intelligent insights and high-resolution directional mapping.6 Additionally, the OPTRELL™ Mapping Catheter has tight electrode spacing and small electrodes, which produce higher signal resolution, resulting in enhanced maps of the heart.7,8 With these high-definition maps, clinicians have a better understanding of where the arrhythmia is occurring and can develop a more effective ablation strategy. "The OPTRELL™ Mapping Catheter has a fixed electrode array structure that provides greater diagnostic insight, which allows physicians to quickly and effectively identify ablation targets," said Pasquale Santangeli, M.D., Ph.D., Cardiovascular Medicine, Cleveland Clinic Main Campus.ii "This catheter and the Local Conduction Vectors give me the confidence to quickly and effectively detect ablation lesion gaps and the arrhythmia substrate, even in the most complex cases, including persistent AFib, redo AFib ablation, atrial tachycardia, and ventricular tachycardia." The OPTRELL™ Mapping Catheter is powered by the CARTO® 3 System, which offers Local Conduction Vectors that display the real-time direction and speed of the electrical impulses traveling through the heart.9 With these Local Conduction Vectors, clinicians gain enhanced understanding of complex circuits and mechanisms and can confidently detect gaps in ablation lesions.7 Together, these technologies can help clinicians quickly identify areas that need ablation and apply more effective therapy in a shorter time. "The OPTRELL™ Mapping Catheter rounds out the Biosense Webster diagnostic mapping portfolio, providing physicians with a comprehensive set of tools, integrated with our CARTO® 3 mapping system, to diagnose and treat arrhythmias," said Jasmina Brooks, President, Biosense Webster, Inc. "This is the latest example of the continued commitment of Biosense Webster to providing clinicians with innovative tools to improve efficiency and effectiveness of procedures and quality of care for patients." The OPTRELL™ Mapping Catheter with TRUEref™ Technology received U.S. Food and Drug Administration (FDA) 510(k) clearance in 2022 and is now available in the U.S. The OPTRELL™ Mapping Catheter with TRUEref™ Technology will be commercially available in Japan later this year. About Biosense Webster Biosense Webster, Inc. is the global market leader in the science and technology behind the diagnosis and treatment of cardiac arrhythmias. Part of Johnson & Johnson MedTech, the specialized medical-technology company is headquartered in Irvine, California, and works across the world to advance the tools and solutions that help electrophysiologists identify, treat, and deliver care. About Johnson & Johnson MedTechi At Johnson & Johnson MedTech,i we unleash diverse healthcare expertise, purposeful technology, and a passion for people to transform the future of medical intervention and empower everyone to live their best life possible. For more than a century, we have driven breakthrough scientific innovation to address unmet needs and reimagine health. In surgery, orthopaedics, vision, and interventional solutions, we continue to help save lives and create a future where healthcare solutions are smarter, less invasive, and more personalized.

Read More

Health Technology, Digital Healthcare

Innovative New Tool Empowers Unprecedented Health Plan Efficiency

businesswire | August 23, 2023

Next-generation healthcare SaaS company HealthEdge® today announced the release of a first-of-its-kind application that makes running a health plan faster and easier than ever. The web-based configuration management tool HealthRules® Promote is available to all HealthRules Payer customers. Born from a unique collaboration between HealthEdge and Minnesota-based nonprofit health plan Medica, HealthRules Promote answers the need for a more efficient, accurate and worry-free way to manage complex health plan offerings across multiple lines of business. In the midst of rapid expansion into eight new states, Medica turned to HealthEdge for help with an increasingly elaborate infrastructure. Together, they developed a powerful solution that gives plans the configuration agility to handle today’s dynamic healthcare demands. In its first year at Medica, HealthRules Promote supported more than 400 configuration projects and yielded an estimated $750,000 cost savings. “For us, HealthRules Promote has been a game changer,” said Robb Tushie-Lessard, manager of configuration architecture, quality and business analysts at Medica. “We are able to empower our multi-user environments with the tools they need to implement new configurations with greater confidence and fewer issues. When we recently rolled our commercial plans onto the HealthRules Payer platform, we experienced zero configuration issues.” Paired with HealthEdge’s next-generation core administrative processing solution, HealthRules Payer, HealthRules Promote enables health plan business analysts to promote and test configuration changes in minutes through a user-friendly interface. Leveraging automation, the application’s controlled workflow saves thousands of hours in manual effort and simplifies the process of updating validation policies, modifying fee schedules, restructuring benefit plans and launching new lines of business. A self-service design alleviates administrative burden and technical resources, empowering analysts to move configurations from testing to production environments without the need for Information Technology (IT) support. A comprehensive audit trail tracks changes automatically, increasing transparency and facilitating build review. Dependency and compare features reduce errors and allow analysts to identify issues with ease. “HealthRules Promote makes health plans nimble and resilient to member, provider, regulatory and competitive pressures in the ever-changing healthcare landscape,” said Alan Stein, chief commercial officer of HealthEdge. “The solution provides unprecedented configuration and promotion integrity that helps HealthRules Payer customers grow, compete and realize maximum value from their core system at an accelerated pace.” About HealthEdge Innovating a world where healthcare can focus on people, HealthEdge® is driving a digital transformation through transaction automation and real-time business and clinical engagement among payers, providers and patients. The next-generation healthcare SaaS company provides an integrated ecosystem of advanced solutions for core administration (HealthRules® Payer), payment integrity (Source), care management (GuidingCare®) and member experience (Wellframe) that empower health plans to accelerate business, reduce costs and improve outcomes.

Read More

Health Technology

TeleVox Secures Odeza's Patient Engagement Unit from Ensemble Health

TeleVox | September 11, 2023

TeleVox and Ensemble will provide Ensemble's clients with an all-encompassing healthcare solution, from patient acquisition to post-discharge care. This announcement is yet another significant milestone in TeleVox's continuous rapid growth and expansion journey. This acquisition underscores TeleVox's commitment to strengthening its presence in the healthcare sector as it integrates Odeza's patient engagement business. TeleVox, a distinguished provider of state-of-the-art omnichannel digital patient engagement technology, has completed a significant acquisition by owning the Odeza patient engagement business from Ensemble Health Partners (Ensemble). Ensemble, recognized as a preeminent force in revenue cycle management, specializes in delivering its services to various healthcare institutions, including hospitals, health systems, and physician practices. TeleVox and Ensemble are committed to extending the reach and accessibility of TeleVox's cutting-edge technology to Ensemble's existing customer base. This strategic endeavor aims to deliver healthcare providers an all-encompassing solution that seamlessly caters to a broad spectrum of healthcare requirements, commencing with the initial patient acquisition phase and extending throughout the entirety of the patient journey. This comprehensive approach encompasses not only the discharge process but extends into subsequent phases of aftercare and beyond, equipping healthcare institutions with the essential tools and resources to optimize patient engagement, streamline operational workflows, and elevate the overall quality of care delivery. Additionally, this move positions TeleVox to enhance its capabilities further in providing innovative solutions, enabling healthcare providers to engage with patients in a more comprehensive and technologically advanced manner, ultimately advancing the healthcare industry. Vik Krishnan, President of TeleVox, expressed his welcome to Odeza joining the TeleVox family and highlighted that the acquisition of Odeza's patient engagement business aligns with TeleVox's longstanding commitment to tailored communication solutions for enhancing the patient experience, solidifying TeleVox's position as an industry leader. He also emphasized that making their patient engagement solutions accessible to Ensemble's extensive customer base will enable more healthcare providers to deliver exceptional patient care. Judson Ivy, Founder, President and CEO of Ensemble Health Partners, remarked, "This partnership strengthens each of our positions in the healthcare industry and delivers unmatched value to our customers." Meanwhile, the company unveiled Iris, an AI-powered omnichannel conversational virtual assistant tailored for healthcare providers, in April. The introduction of an automated reputation management solution in the month that followed this significant development gave hospitals, health systems, and physician practices the ability to manage and improve their online presence effectively.

Read More

Health Technology

Biosense Webster Launches the OPTRELL™ Mapping Catheter with TRUEref™ Technology for Mapping of Complex Cardiac Arrhythmias

PRNewswire | July 25, 2023

Biosense Webster, Inc., a global leader in cardiac arrhythmia treatment and part of Johnson & Johnson MedTech,i announced the U.S. launch of the OPTRELL™ Mapping Catheter with TRUEref™ Technology powered by the CARTO® 3 System. The OPTRELL™ Mapping Catheter is a high-density diagnostic catheter, with small electrodes arranged in a fixed array formation to provide high-definition electrophysiological mapping of complex cardiac arrhythmia cases like persistent atrial fibrillation (AFib), redo AFib ablation, atrial tachycardia, and ventricular tachycardia. Cardiac arrhythmias are a growing epidemic. AFib is the most common type of cardiac arrhythmia and impacts nearly 40 million people worldwide, with up to 6 million of these individuals living in the U.S.1,2 AFib is a progressive disease, and if left untreated can get worse over time or lead to other serious complications like heart disease or stroke.3,4 Catheter ablation is a safe and effective procedure to restore the heart's incorrect electrical signals, which causes an abnormal heart rhythm.5 This new catheter includes 48 electrodes symmetrically distributed across and along six splines and combines with the CARTO® 3 System to deliver intelligent insights and high-resolution directional mapping.6 Additionally, the OPTRELL™ Mapping Catheter has tight electrode spacing and small electrodes, which produce higher signal resolution, resulting in enhanced maps of the heart.7,8 With these high-definition maps, clinicians have a better understanding of where the arrhythmia is occurring and can develop a more effective ablation strategy. "The OPTRELL™ Mapping Catheter has a fixed electrode array structure that provides greater diagnostic insight, which allows physicians to quickly and effectively identify ablation targets," said Pasquale Santangeli, M.D., Ph.D., Cardiovascular Medicine, Cleveland Clinic Main Campus.ii "This catheter and the Local Conduction Vectors give me the confidence to quickly and effectively detect ablation lesion gaps and the arrhythmia substrate, even in the most complex cases, including persistent AFib, redo AFib ablation, atrial tachycardia, and ventricular tachycardia." The OPTRELL™ Mapping Catheter is powered by the CARTO® 3 System, which offers Local Conduction Vectors that display the real-time direction and speed of the electrical impulses traveling through the heart.9 With these Local Conduction Vectors, clinicians gain enhanced understanding of complex circuits and mechanisms and can confidently detect gaps in ablation lesions.7 Together, these technologies can help clinicians quickly identify areas that need ablation and apply more effective therapy in a shorter time. "The OPTRELL™ Mapping Catheter rounds out the Biosense Webster diagnostic mapping portfolio, providing physicians with a comprehensive set of tools, integrated with our CARTO® 3 mapping system, to diagnose and treat arrhythmias," said Jasmina Brooks, President, Biosense Webster, Inc. "This is the latest example of the continued commitment of Biosense Webster to providing clinicians with innovative tools to improve efficiency and effectiveness of procedures and quality of care for patients." The OPTRELL™ Mapping Catheter with TRUEref™ Technology received U.S. Food and Drug Administration (FDA) 510(k) clearance in 2022 and is now available in the U.S. The OPTRELL™ Mapping Catheter with TRUEref™ Technology will be commercially available in Japan later this year. About Biosense Webster Biosense Webster, Inc. is the global market leader in the science and technology behind the diagnosis and treatment of cardiac arrhythmias. Part of Johnson & Johnson MedTech, the specialized medical-technology company is headquartered in Irvine, California, and works across the world to advance the tools and solutions that help electrophysiologists identify, treat, and deliver care. About Johnson & Johnson MedTechi At Johnson & Johnson MedTech,i we unleash diverse healthcare expertise, purposeful technology, and a passion for people to transform the future of medical intervention and empower everyone to live their best life possible. For more than a century, we have driven breakthrough scientific innovation to address unmet needs and reimagine health. In surgery, orthopaedics, vision, and interventional solutions, we continue to help save lives and create a future where healthcare solutions are smarter, less invasive, and more personalized.

Read More

Health Technology, Digital Healthcare

Innovative New Tool Empowers Unprecedented Health Plan Efficiency

businesswire | August 23, 2023

Next-generation healthcare SaaS company HealthEdge® today announced the release of a first-of-its-kind application that makes running a health plan faster and easier than ever. The web-based configuration management tool HealthRules® Promote is available to all HealthRules Payer customers. Born from a unique collaboration between HealthEdge and Minnesota-based nonprofit health plan Medica, HealthRules Promote answers the need for a more efficient, accurate and worry-free way to manage complex health plan offerings across multiple lines of business. In the midst of rapid expansion into eight new states, Medica turned to HealthEdge for help with an increasingly elaborate infrastructure. Together, they developed a powerful solution that gives plans the configuration agility to handle today’s dynamic healthcare demands. In its first year at Medica, HealthRules Promote supported more than 400 configuration projects and yielded an estimated $750,000 cost savings. “For us, HealthRules Promote has been a game changer,” said Robb Tushie-Lessard, manager of configuration architecture, quality and business analysts at Medica. “We are able to empower our multi-user environments with the tools they need to implement new configurations with greater confidence and fewer issues. When we recently rolled our commercial plans onto the HealthRules Payer platform, we experienced zero configuration issues.” Paired with HealthEdge’s next-generation core administrative processing solution, HealthRules Payer, HealthRules Promote enables health plan business analysts to promote and test configuration changes in minutes through a user-friendly interface. Leveraging automation, the application’s controlled workflow saves thousands of hours in manual effort and simplifies the process of updating validation policies, modifying fee schedules, restructuring benefit plans and launching new lines of business. A self-service design alleviates administrative burden and technical resources, empowering analysts to move configurations from testing to production environments without the need for Information Technology (IT) support. A comprehensive audit trail tracks changes automatically, increasing transparency and facilitating build review. Dependency and compare features reduce errors and allow analysts to identify issues with ease. “HealthRules Promote makes health plans nimble and resilient to member, provider, regulatory and competitive pressures in the ever-changing healthcare landscape,” said Alan Stein, chief commercial officer of HealthEdge. “The solution provides unprecedented configuration and promotion integrity that helps HealthRules Payer customers grow, compete and realize maximum value from their core system at an accelerated pace.” About HealthEdge Innovating a world where healthcare can focus on people, HealthEdge® is driving a digital transformation through transaction automation and real-time business and clinical engagement among payers, providers and patients. The next-generation healthcare SaaS company provides an integrated ecosystem of advanced solutions for core administration (HealthRules® Payer), payment integrity (Source), care management (GuidingCare®) and member experience (Wellframe) that empower health plans to accelerate business, reduce costs and improve outcomes.

Read More

More featured news